Business Wire

AHS Properties Acquires Shangri-La Hotel for AED 1.1 Billion in Landmark Sheikh Zayed Road Transaction

11.6.2026 09:00:00 EEST | Business Wire | Press release

Share

AHS Properties today announced the acquisition of Shangri-La Hotel for AED 1.1 billion, one of the largest single-asset real estate transactions recorded in recent history.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605096792/en/

Shangri-La Hotel Exterior, Sheikh Zayed Road. (Photo: AETOSWire)

Acquired from Mismak Asset Management, the transaction cements one of the most concentrated private-sector bets on Sheikh Zayed Road's next decade.

The Shangri-La Hotel is a 43-floor, 200-metre tower on Sheikh Zayed Road, and was one of the first five-star hotels to open on the corridor when it was completed in 2003.

The acquisition adds an iconic anchor asset to a portfolio that already includes AHS Tower, a recently sold-out Grade-A commercial development on Sheikh Zayed Road, and AHS City, the developer’s flagship master-planned, mixed-use community on the corridor with a forecast gross development value of AED 25 billion.

Together, these three assets form a vertical corridor play: AHS Tower, AHS City, and now Shangri-La Hotel. The combined footprint represents a significant share of AHS Properties' AED 50 billion year-end 2026 pipeline.

We did not buy a hotel. We bought a position on a corridor where supply is structurally constrained and demand is globally diversified. This is more than an acquisition for AHS Properties. It’s a statement of our long-term confidence in Dubai, in the strength of its real estate sector, and in its continued appeal to global capital," said Abbas Sajwani, Founder and CEO of AHS Properties.

The acquisition reflects AHS Properties strategy of deploying capital into structurally constrained assets. According to the Dubai Land Department, the emirate's real estate sector recorded AED 252 billion in transactions in the first quarter of 2026. Foreign investment rose 26 per cent to AED 148.35 billion, with the investor base reaching 48,448.

The Shangri-La Hotel sits on land that will not be released again. The first five-star hotels on Sheikh Zayed Road were built once, more than twenty years ago. This is not a deal that anyone, including us, will be able to do twice. That is the reason this acquisition makes sense at this scale,” added Sajwani.

The acquisition has no impact on the hotel’s day-to-day operations, and guests can continue to enjoy the exceptional service and hospitality they have come to expect. The property remains an important part of AHS Properties’ broader Sheikh Zayed Road portfolio.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260605096792/en/

Contacts

Tammy Atlee, Communications Director, tammy.atlee@ahs-properties.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wolters Kluwer enhances its Libra legal AI workspace in Italy by adding content specializations for One and integrating with Kleos11.6.2026 10:00:00 EEST | Press release

Wolters Kluwer Legal & Regulatory announced today new content and feature integrations in its legal AI workspace Libra by Wolters Kluwer for the Italian market. Customers will have access to additional expert-generated content in compliance, criminal law and tax law, and profit from the integration with Kleos, the cloud-based practice management solution for law firms. Designed to support the daily work of legal professionals, Libra by Wolters Kluwer combines advanced AI functionalities with trusted sources and authoritative, author-generated legal content. Within a single environment, it enables research, analysis and drafting activities based on reliable sources, while maintaining full control over results and quality. By integrating additional expert content from One, Wolters Kluwer’s leading legal research platform, Libra offers even more focused and up-to-date content, enabling more precise analysis of specific topics, and foster direct integration between legal research and opera

Pleo Announces New Agentic Capabilities, Changing the Face of Financial Management and Decision-Making11.6.2026 10:00:00 EEST | Press release

Pleo, Europe's first and most trusted strategic finance platform, today announces a suite of AI agents that handle routine spend management autonomously, so finance leaders can focus on decisions rather than administrative tasks. Finance teams are under growing pressure: 45% of European companies say their current processes slow them down, and leaders describe approval workflows as so cumbersome they struggle to operate at the required speed. Meanwhile, 73% believe the future of finance teams and professionals depends on the comprehensive understanding and use of AI, yet 63% say AI skills, training and confidence are severely lagging. Pleo's agentic AI addresses this gap. Starting with beta testing in July, Pleo is moving toward a model where specialised agents execute routine work autonomously, surfacing only the exceptions that genuinely need human judgment. Jeppe Rindom, CEO and Founder of Pleo comments: “Agentic AI gives finance leaders a clear path out of the admin and back to the

Vertex Presents New Data on CASGEVY ® , Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions11.6.2026 09:01:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, from pivotal studies in children ages 5–11, show that the efficacy and safety outcomes in this age group are consistent with the transformative profile established in adult and adolescent patients. These data were presented at the European Hematology Association (EHA) Congress and simultaneously published in the New England Journal of Medicine (NEJM). “The data presented at EHA and published in NEJM underscore the consistent, durable and transformative benefits CASGEVY can provide to people living with sickle cell disease or transfusion-dependent beta thalassemia from early in life,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Off

PUMA Brings NITRO™ to Football With the PUMA NITRO Lab in Los Angeles11.6.2026 09:00:00 EEST | Press release

Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and NITRO™'s arrival in football for the first time on a football boot. Previous editions of the NITRO™ Lab in Paris, Tokyo, and London explored the future of running performance and cemented NITRO™ as the defining technology in elite running with Fast-R3. Now, with the world’s attention turning to football, Los Angeles is where that journey takes its next step, introducing the same innovation DNA that reshaped the track to the pitch, when it matters most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610728823/en/ Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and N

Curatis Increases Revenue Growth Guidance for 202611.6.2026 08:00:00 EEST | Press release

Curatis Holding AG (SIX: CURN) increases its revenue growth guidance for the financial year 2026: the company is forecasting a revenue growth of approximately 40% in 2026, in contrast to the previous outlook of over 25%. Based on preliminary figures for the first five months of 2026, Curatis expects a significantly higher than anticipated revenue growth for 2026. This growth is driven by products that Curatis has marketed for some time, as well as by products added to its portfolio in 2025 and 2026. Under the new guidance, Curatis projects revenues of approximately CHF 15m in 2026, up from CHF 10.8m in 2025. Curatis will publish detailed financial figures for the first six months of 2026 in the half-year report on 21 September 2026. About Curatis Curatis Holding AG is a publicly listed company (CURN.SW) focused on the late stage development and commercialization of drugs for rare diseases and specialty care. Curatis has a sales portfolio of more than 40 products and a pipeline of orpha

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye